Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal carcinoma

* Stage II, III, or IV disease with optimal (=\< 1 cm residual disease) or suboptimal residual disease

* All patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, with appropriate tissue for histologic evaluation

* The minimum surgery required is an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking; if additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the Gynecologic Oncology Group (GOG) Surgical Procedures Manual

Patients with the following histologic epithelial cell types are eligible:

* Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.)

* However, the histologic features of the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma; if doubt exists, it is recommended that the investigator should have the slides reviewed by an independent pathologist prior to entry

* Patients may have co-existing endometrial cancer so long as the primary origin of invasive tumor is ovarian or peritoneal for clarification of synchronous primary endometrial cancer

Patients receiving the initial course of chemotherapy including

* Paclitaxel 135 mg/M2 IV over 3 hours on day 1 and

* Cisplatin 75 mg/M2 IP on day 2 OR

* Paclitaxel 80 mg/m2 IV days 1, 8 and 15 and

* Carboplatin AUC 6 IP on day 1

Prothrombin time (PT) such that international normalized ratio (INR) is \< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)

Partial thromboplastin time (PTT) \< 1.5 times the upper limit of normal (heparin, lovenox or alternative anticoagulants are acceptable)

Patients with a GOG Performance Status of 0, 1, or 2

Patients who are able to read, understand and write English; if FLIE which has been translated into other languages, and validated, becomes available, then patients speaking these languages can be enrolled if translation of the symptom diary can be arranged dependent on availability of suitable translators

Patients who are able to complete the assessments

Patients who are able to comply with the anti-emetic therapy

Patients must have met pre-entry requirements

Patients must have signed an approved informed consent and authorization permitting release of personal health information

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

What this study is about

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

What this study is about